Thyrocare Technologies Ltd (BOM:539871)

Q2 2026 Thyrocare Technologies Ltd Earnings Call Transcript

Oct 14, 2025 / 12:00 PM GMT

Release Date Price: ₹421.53 (+0.12%)

Transcript

Key Points

Positve

Thyrocare Technologies Ltd (BOM:539871) announced a bonus share issuance in the proportion of 2 to 1, reflecting strong performance and confidence in future growth.
The company reported a 22% year-on-year revenue growth, driven primarily by a 24% increase in the pathology business.
Franchisee network expansion has been robust, with over 10,100 active quarterly franchisees, up from 8,446 in the same quarter last year.
Operational efficiency improvements have led to a gross margin increase to 71.6%, up by 100 basis points.
The company has achieved 100% NABL accreditation across all labs, underscoring its commitment to quality and excellence in diagnostics.

Negative

Fever-related volumes were down 26% compared to the same quarter last year, impacting seasonal revenue.
The B2G business remains a small focus, contributing only about 1% to total revenue, with low price realizations and margin dilution.
Despite strong growth, the radiology business showed only a modest revenue increase of 3% year-on-year.
Revenue per test and per patient remains low, attributed to the company's focus on affordability rather than price increases.
The company faces challenges in maintaining growth momentum in the face of a strong base from the previous year and potential headwinds in the upcoming quarters.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

THYO.NS - Thyrocare Technologies Ltd
Q2 2026 Thyrocare Technologies Ltd Earnings Call
Oct 14, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
And must be viewed in relation to the risk pertaining to our business.

After the end of this call, in case you have any further questions, please feel free to reach out to the investor relations team.

I now hand over the call to Mr. Rahulhua to make the opening remarks over to you Raul.

Thank you, Preet.

Good evening and welcome to All On The Call.

Thank you for taking our time from your busy schedules to join us this evening.

Just a quick introduction to us on the call. My name is Rahul Buha and I'm the MD and CEO of Cyrocare, and thank you for the opportunity to present the Q2 results for FY26.

I'm joined with my colleague Vikram Gupta, who is our CFO,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.